Search

Displaying results 5381 - 5390 of 10000 in total
  1. Drug

    Rabeximod

    go.drugbank.com/drugs/DB05772
    Investigational

    Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.

  2. Drug

    Ethyl biscoumacetate

    go.drugbank.com/drugs/DB08794
    ApprovedWithdrawn

    It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)

  3. Drug

    Adenosine 5'-phosphosulfate

    go.drugbank.com/drugs/DB03708
    Investigational

    The initial compound formed by the action of ATP sulfurylase on sulfate ions after sulfate uptake. Synonyms: adenosine sulfatophosphate; APS.

  4. Drug

    Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15731
    Investigational

    ORBCEL-C™ is the trade name of a product composed of highly purified stromal cells derived from the human umbilical cord. … Enrichment of CD362 expression in MSCs is being investigated for its role in immune modulation of injured tissue.

  5. Drug

    Nizubaglustat

    go.drugbank.com/drugs/DB21603
    Investigational

    C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis). … Nizubaglustat has a monoisotopic molecular weight of 433.23 Da.

  6. Drug

    Bradanicline

    go.drugbank.com/drugs/DB06090
    Investigational

    Bradanicline belongs to a new class of drugs for the treatment of central nervous system diseases and disorders. … Bradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(α7).

  7. Drug

    ATL1101

    go.drugbank.com/drugs/DB05023
    Experimental

    ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis. … ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis.

  8. Drug

    Ralmitaront

    go.drugbank.com/drugs/DB19128
    Investigational

    Ralmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or

  9. Drug

    AZD-8330

    go.drugbank.com/drugs/DB06061
    Investigational

    AZD-8330 has shown tumor suppressive activity in multiple preclinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.

  10. Drug

    Galicaftor

    go.drugbank.com/drugs/DB14894
    Investigational

    Galicaftor is under investigation in clinical trial NCT03540524 (A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737